```html

Zidovudine (AZT) Resistance in HIV

Overview

Zidovudine resistance refers to the ability of human immunodeficiency virus (HIV) to replicate despite the presence of the antiretroviral drug zidovudine (also known as AZT or Retrovir). Zidovudine is a nucleoside reverse‑transcriptase inhibitor (NRTI) that was the first drug approved for HIV treatment in 1987. While it remains a component of many combination regimens, the virus can acquire mutations that reduce AZT’s effectiveness, leading to what clinicians call “AZT‑resistant HIV.”

Anyone living with HIV who is prescribed zidovudine can develop resistance, but the risk is highest in the following groups:

• People who start zidovudine as monotherapy or in an incomplete regimen.
• Individuals with poor adherence (<90% of doses taken) over a prolonged period.
• Patients whose virus already carries resistance‑associated mutations from prior therapy.

According to the World Health Organization (WHO), about 15‑20% of patients on first‑line NRTI‑based regimens in low‑ and middle‑income countries develop at least one NRTI resistance mutation within two years. In the United States, surveillance data from the CDC show that AZT‑associated mutations are present in roughly 5–8% of treatment‑experienced individuals.

Symptoms

Resistance itself does not cause a unique set of symptoms; instead, it manifests as a loss of virologic control. When zidovudine is no longer suppressing the virus, the patient may experience the usual signs of HIV disease progression or opportunistic infections. Typical “symptoms of virologic failure” include:

General HIV‑Related Symptoms

• Fever or night sweats – Persistent low‑grade fever may indicate viral replication or an opportunistic infection.
• Unexplained weight loss – Losing >10% body weight unintentionally over 6 months.
• Chronic fatigue – Profound tiredness not relieved by rest.
• Swollen lymph nodes – Especially in the neck, armpits, or groin.
• Oral thrush – White patches on the tongue or inside the mouth.
• Recurrent diarrhea – May be caused by HIV enteropathy or infection.
• Skin rashes or lesions – Including herpes zoster, Kaposi sarcoma, or generalized rash.

Signs of Specific Opportunistic Infections (OIs) that may appear when resistance leads to immune decline

• Pneumocystis jirovecii pneumonia (PCP) – Shortness of breath, dry cough, low‑grade fever.
• Cytomegalovirus (CMV) retinitis – Blurred vision, floaters, painless vision loss.
• Tuberculosis (TB) – Persistent cough, weight loss, night sweats, hemoptysis.
• Cryptococcal meningitis – Severe headache, neck stiffness, fever, altered mental status.

Because these manifestations are not exclusive to zidovudine resistance, regular laboratory monitoring is essential to detect resistance before clinical deterioration.

Causes and Risk Factors

How Resistance Develops

Zidovudine inhibits the HIV reverse‑transcriptase enzyme, preventing the conversion of viral RNA into DNA. The virus’s reverse‑transcriptase lacks proofreading ability, leading to frequent mutations during replication. When a mutation reduces zidovudine’s binding affinity, the drug becomes less effective. The most recognized AZT‑resistance mutations are:

• M184V/I – Confers high‑level resistance to lamivudine but also influences AZT susceptibility.
• Thymidine‑associated mutations (TAMs) – A series of mutations (e.g., M41L, D67N, K70R, L210W, T215Y/F, K219Q/E) that cumulatively increase AZT resistance.
• K65R – Reduces susceptibility to multiple NRTIs, including AZT.

Major Risk Factors

• Poor medication adherence – Missing doses creates sub‑therapeutic drug levels, giving the virus a window to mutate.
• Monotherapy or incomplete regimens – Using AZT without a second active drug (e.g., as a “kick‑back” after stopping therapy) dramatically raises resistance risk.
• Prior exposure to NRTIs – Existing TAMs from earlier regimens make later AZT use less effective.
• High baseline viral load – More virus means more replication cycles, increasing the odds of a resistant mutant emerging.
• Co‑infection with hepatitis B or C – May complicate drug selection and adherence.
• Suboptimal pharmacokinetics – Drug interactions (e.g., with certain antacids) that lower AZT plasma concentrations.

Diagnosis

Detecting zidovudine resistance relies on a combination of clinical observation, laboratory viral load testing, and specialized genotypic/phenotypic resistance assays.

1. Routine Viral Load Monitoring

The first clue is a rising HIV‑RNA level after an initial suppression. Current guidelines (CDC, WHO, HIV Medicine 2023) recommend checking plasma HIV‑1 RNA every 3–6 months for stable patients and within 4 weeks after any regimen change.

2. CD4+ T‑Cell Count

A declining CD4 count (e.g., <10–20 cells/µL per month) alongside increasing viral load supports treatment failure, prompting resistance testing.

3. Genotypic Resistance Testing (GRT)

• Obtains viral RNA from plasma, amplifies the reverse‑transcriptase gene, and sequences it.
• Identifies specific mutations (e.g., TAMs, K65R).
• Results are typically returned within 1–2 weeks.
• Recommended when viral load >1,000 copies/mL after ≥6 months of therapy.

4. Phenotypic Resistance Testing

Measures the actual drug concentration needed to inhibit the patient’s virus in vitro. It is more expensive and often reserved for complex cases where genotypic results are inconclusive.

5. Drug‑Level Monitoring (optional)

In selected patients, measuring zidovudine plasma concentrations can uncover adherence issues or drug–drug interactions that mimic resistance.

Treatment Options

Once AZT resistance is confirmed, the goal is to construct a new regimen that achieves durable viral suppression while minimizing toxicity.

1. Switch to an Optimized Combination Antiretroviral Therapy (cART)

• Integrase strand transfer inhibitors (INSTIs) – e.g., dolutegravir, bictegravir – have high barriers to resistance and are now first‑line per WHO 2022 guidelines.
• Second‑generation NNRTIs – e.g., doravirine – may be used if no NNRTI resistance is present.
• Protease inhibitors (PIs) boosted with ritonavir or cobicistat – e.g., darunavir/ritonavir – are effective against many NRTI‑resistant strains.
• Newer NRTIs with activity despite TAMs – e.g., tenofovir alafenamide (TAF) or lamivudine + dolutegravir dual therapy (in select patients).

2. Use of “Recycling” NRTIs

If only a few TAMs are present, a high‑genetic‑barrier drug (like dolutegravir) paired with a partially active NRTI (e.g., tenofovir) can maintain a simpler regimen. This strategy requires careful resistance‑interpretation software (e.g., Stanford HIV Drug Resistance Database).

3. Management of Side Effects

• Bone marrow suppression – Monitor CBC; consider granulocyte‑colony stimulating factor (G‑CSF) if severe neutropenia.
• Anemia – Treat with iron, folate, or erythropoietin‑stimulating agents; switch to a non‑myelosuppressive regimen.
• GI intolerance – Take medication with food, use anti‑emetics, or switch to a better‑tolerated formulation.

4. Adjunctive Therapies

Vaccination (influenza, pneumococcal, HPV, hepatitis B), prophylaxis for OIs (e.g., TMP‑SMX for PCP when CD4 <200), and treatment of co‑infections are essential components of comprehensive care.

5. Lifestyle Measures

• Adopt a balanced diet rich in protein, iron, and folate to support hematopoiesis.
• Engage in regular physical activity to maintain muscle mass and cardiovascular health.
• Avoid smoking and limit alcohol, as both can worsen bone‑marrow toxicity.

Living with Zidovudine Resistance (HIV)

Medication Management

• Use a pill‑box or smartphone reminder to achieve >95% adherence.
• Keep a medication diary; share it with your clinician at each visit.
• Never stop or change a drug without consulting your HIV specialist.

Monitoring & Follow‑Up

• Viral load every 3 months until two consecutive < 50 copies/mL, then every 6 months.
• CD4 count every 6–12 months, or more often if declining.
• Annual resistance testing if you experience a rebound or switch regimens.

Psychosocial Support

• Join peer‑support groups (e.g., local AIDS service organizations).
• Seek counseling for medication‑related anxiety or stigma.
• Consider financial assistance programs for antiretrovirals (e.g., ADAP in the U.S.).

Self‑Care Tips

• Stay hydrated; AZT can cause nausea and loss of appetite.
• Maintain a regular sleep schedule to support immune function.
• Track any new symptoms and report them promptly—early detection of OIs prevents severe disease.

Prevention

Because resistance is a consequence of treatment, preventing it focuses on optimal use of antiretrovirals and reducing the need for zidovudine in the first place.

• Start treatment with a modern, high‑barrier regimen (e.g., INSTI‑based) whenever possible.
• Adhere strictly to prescribed dosing—missed doses are the single biggest driver of resistance.
• Never use zidovudine monotherapy or discontinue therapy without medical guidance.
• Regularly review drug–drug interactions with a pharmacist, especially with over‑the‑counter meds and supplements.
• Pre‑exposure prophylaxis (PrEP) for at‑risk HIV‑negative individuals reduces the pool of new infections, thereby limiting the future need for zidovudine.

Complications

If zidovudine resistance is not identified and addressed promptly, several complications may arise:

• Progressive immunodeficiency – Ongoing viral replication drives CD4 decline, increasing susceptibility to opportunistic infections.
• Treatment‑limited options – Accumulation of multiple NRTI mutations may restrict future regimen choices, especially in resource‑limited settings.
• Increased morbidity and mortality – Cohort studies (e.g., NA‑ACCORD, 2021) link uncontrolled viremia to a 2–3‑fold higher risk of AIDS‑defining events.
• Drug‑related toxicities – Continuing AZT despite resistance can exacerbate anemia, neutropenia, and myopathy.
• Transmission risk – Higher plasma viral loads raise the chance of transmitting HIV to partners.

When to Seek Emergency Care

---

Sources: Mayo Clinic, CDC, WHO, NIH (HIV.gov), Cleveland Clinic, Stanford HIV Drug Resistance Database, NA‑ACCORD cohort publications (2021‑2023).

```